CSF2 and B-cell chronic lymphocytic leukemia: In comparison with GM-CSF and IL-4 or PBS treatments, CLL cells treated with GIFT4 significantly enhanced the long-term survival and expansion of T cells from CLL patients in the NSG mice (Fig. 5b, c).